Huili Biotechnology completes Series A financing

Jiangsu Huili Biotechnology, a next-generation synthetic biology enzyme computational design platform, has recently announced the completion of its Series A financing round with hundreds of million RMB. This financing round was co-led by Legend Capital and the fresh capital will be used to accelerate the construction and operation of large-scale production facilities, the R&D of new product pipelines and the expansion of the talent team. Founded in 2018, Huili Bio is dedicated to the computational design of enzyme components at the core of synthetic biological reactions. With cutting-edge achievements, Huili Bio is one of the few bio-manufacturing companies with comprehensive capabilities in core technology, mass production on a large scale and closed-loop commercialisation. It provides solutions in multiple fields such as pharmaceutical intermediates, animal protection and food. In addition to an R&D centre in Tianjin, Huili Bio has also established a production base in Taizhou City, Jiangsu Province, which is under the expansion of flexible production lines.